The potential of trastuzumab deruxtecan as a tissue agnostic drug

Oncology. 2023 Aug 31. doi: 10.1159/000533866. Online ahead of print.ABSTRACTBACKGROUND: Many modern anticancer drugs are designed to target specific molecular alterations harbored by the cancer. If a specific drug is able to target these alterations, regardless of the organ or tissue in which the cancer originates, it will often be characterized as a tissue- or tumor agnostic drug. According to the Food and Drug Administration (FDA), a tissue agnostic drug refers to a drug that targets a specific molecular alteration across multiple cancer types, as defined by organ, tissue, or tumor type.SUMMARY: Over the last six years, the FDA has approved seven tissue agnostic drugs, and more are anticipated in the future. One promising candidate for a tissue agnostic classification is the antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Currently, T-DXd is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive and HER2-low breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, and non-small cell lung cancer with activating HER2 mutations. Ongoing clinical research is exploring the potential of T-DXd in various solid tumors that harbor specific HER2 molecular alterations, and encouraging results, including the interim data from the DESTINY-PanTumor02 trial, have been published, which suggest a tissue agnostic potential.KEY MESSAGES: Published phase I data as well as the interim results from the phase II DESTINY-PanTumor02 ...
Source: Oncology - Category: Cancer & Oncology Authors: Source Type: research